Renalytix Q3 revenue $0.5M; net loss $7.7M; strategic sale process initiated

Renalytix plc

2024-Q3 EPS reported -$0.27 revenue$1,703,000

Revenue of $0.5M, down from $0.7M YoY; net loss narrowed to $7.7M from $12.1M.
Cash and equivalents $4.7M; operating cash burn $4.9M, down ~40% from prior quarter.
Total test volume 806 (82% billable); primary care orders up 33% QoQ.
Strategic sale process initiated with multiple potential acquirers in discussions.
FDA-authorized kidneyintelX.dkd launched April 2024; Medicare coverage draft issued.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Renalytix plc reported the fiscal third quarter ended March 31, 2024 results: revenue $0.5 million, net income Net loss was $7.7 million.

Period: the fiscal third quarter ended March 31, 2024
Revenue: $0.5 million
Net income: Net loss was $7.7 million
Result: reported results

Exact text from the filing

During the three months ended March 31, 2024, the Company recognized $0.5 million of revenue, compared to $0.7 million for the three months ended March 31, 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Renalytix plc filing history →

Source: SEC EDGAR

accession 0000950170-24-060026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.